The ketogenic diet in children with epilepsy

D Papandreou1, E Pavlou, E Kalimeri

  • 1Neurology Department, 2nd Pediatric Clinic, Medical School of Aristotelion University of Thessaloniki, Greece. vellada@otenet.gr

Insights

The ketogenic diet offers a potential treatment for children with epilepsy, particularly those with intractable seizures. Further research is needed to fully understand its mechanisms and ensure safe application, especially regarding growth.

Area of Science:

  • Neurology
  • Metabolic Disorders
  • Pediatric Epilepsy

Background:

  • Epilepsy significantly impacts children's quality of life, with many experiencing intractable seizures.
  • Existing anti-epileptic drugs have limitations, driving the search for alternative, effective treatments with reduced toxicity.
  • The ketogenic diet is a metabolic therapy involving high fat, low carbohydrate, and adequate protein intake.

Purpose of the Study:

  • To review proposed mechanisms of the ketogenic diet's action in epilepsy.
  • To evaluate the efficacy of the ketogenic diet in epileptic children.
  • To identify gaps in current research regarding the diet's risks and benefits.

Main Methods:

  • Literature review of previous and current studies on the ketogenic diet for epilepsy.
  • Analysis of proposed mechanisms related to metabolism and brain energetics.
  • Assessment of reported efficacy and potential risks from existing research.

Main Results:

  • The ketogenic diet aims to induce ketonaemia through specific macronutrient manipulation.
  • Evidence suggests potential efficacy, but studies are often small and short-term.
  • Data on the diet's risks, particularly concerning growth in children, are inconclusive.

Conclusions:

  • The ketogenic diet is a recognized therapy for pediatric epilepsy, modulating metabolism and brain energy.
  • While promising, its precise mechanisms and long-term safety, especially for growth, require further investigation.
  • Clarifying the ketogenic diet's mechanisms will enhance its application for vulnerable pediatric populations.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...